Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Commentary|Videos|November 22, 2024
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma
Author(s)Rimas V. Lukas, MD
Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.
Advertisement
Rimas V. Lukas, MD, neuro-oncologist, associate professor, Neurology, Northwestern University Feinberg School of Medicine, discusses key efficacy data and implications from the phase 3 STELLAR trial (NCT02796261) evaluating eflornithine plus lomustine vs lomustine in patients with recurrent IDH-mutant anaplastic astrocytoma per 2021 World Health Organization diagnostic criteria.
Advertisement
Related to this article
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.
Early phase 2 data showed a median OS of 29.3 months with BPM31510 plus chemoradiation in an MGMT-unmethylated subgroup of treatment-naive glioblastoma.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
In a phase 3 trial analysis, DCVax-L extended OS compared with individual patient data from external control populations in patients with glioblastoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5